Patents by Inventor Justin Hean

Justin Hean has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EXOSOMES COMPRISING THERAPEUTIC POLYPEPTIDES
    Publication number: 20230201370
    Abstract: The present invention pertains to an inventive release mechanism for extracellular vesicle (EV)-mediated intracellular and intramembrane delivery of therapeutic polypeptides. More specifically, the invention relates to EVs comprising polypeptide constructs which comprise a therapeutic polypeptide releasably attached to an exosomal polypeptide. Furthermore, the present invention pertains to manufacturing methods, pharmaceutical compositions, medical uses and applications, and various other embodiments related to the inventive EVs.
    Type: Application
    Filed: November 21, 2022
    Publication date: June 29, 2023
    Inventors: Justin HEAN, Imre MAGER, Matthew WOOD, Samir EL ANDALOUSSI, Oscar WIKLANDER, Joel NORDIN
  • Exosomes comprising therapeutic polypeptides
    Patent number: 11534499
    Abstract: The present invention pertains to an inventive release mechanism for extracellular vesicle (EV)-mediated intracellular and intramembrane delivery of therapeutic polypeptides. More specifically, the invention relates to EVs comprising polypeptide constructs which comprise a therapeutic polypeptide releasably attached to an exosomal polypeptide. Furthermore, the present invention pertains to manufacturing methods, pharmaceutical compositions, medical uses and applications, and various other embodiments related to the inventive EVs.
    Type: Grant
    Filed: May 25, 2017
    Date of Patent: December 27, 2022
    Assignees: Evox Therapeutics Ltd., Oxford University Innovation Limited
    Inventors: Justin Hean, Imre Mager, Matthew Wood, Samir El Andaloussi, Oscar Wiklander, Joel Nordin
  • EXTRACELLULAR VESICLES FOR REPLACEMENT OF UREA CYCLE PROTEINS & NUCLEIC ACIDS
    Publication number: 20210386868
    Abstract: The present invention relates to engineered extracellular vesicles (EVs) as a novel therapeutic approach to treating urea cycle disorders. More specifically, the invention relates to the use of various protein engineering and nucleic acid engineering strategies for improving loading of urea cycle proteins or nucleic acids encoding urea cycle proteins into EVs and targeting of the resultant EVs to tissues and organs of interest.
    Type: Application
    Filed: November 18, 2019
    Publication date: December 16, 2021
    Inventors: Justin HEAN, Harsh AMIN, Virginia CASTILLA LLORENTE
  • Exosomes Comprising RNA Therapeutics
    Publication number: 20210369865
    Abstract: The present invention pertains to extracellular vesicle (EV) therapeutics, wherein the EVs comprise nucleic acid (NA)-based therapeutics such as mRNAs, circular RNAs, miRNAs, shRNAs, circular RNA and/or DNA molecules. The NA therapeutics are loaded into EVs using inventive engineering protein and NA engineering strategies to enhance loading into EVs and to facilitate release of the NA cargo molecules inside target cells.
    Type: Application
    Filed: November 8, 2018
    Publication date: December 2, 2021
    Inventors: Lorenzo ERRICHELLI, Dhanu GUPTA, Justin HEAN, Joel NORDIN
  • Engineering Extracellular Vesicles for Affinity Purification
    Publication number: 20210238248
    Abstract: The present invention pertains to affinity-based isolation and purification of drug-loaded extracellular vesicles, notably exosomes, wherein the exosomes are engineered to enable affinity purification.
    Type: Application
    Filed: June 11, 2019
    Publication date: August 5, 2021
    Inventors: Virginia Castilla LLORENTE, Per LUNDIN, Justin HEAN, Harsh AMIN
  • INTRACELLULAR DELIVERY OF TARGET-SILENCING PROTEIN
    Publication number: 20210062166
    Abstract: The present invention relates to extracellular vesicle (EV)-mediated delivery of protein-based therapeutics. More specifically, the invention relates to delivery of complex polypeptide-based agents which typically bind to target proteins extracellularly, intracellularly, or in the cell membrane.
    Type: Application
    Filed: January 18, 2019
    Publication date: March 4, 2021
    Inventors: Joel NORDIN, Justin HEAN, Per LUNDIN
  • Protein engineered extracellular vesicles
    Publication number: 20200399591
    Abstract: The present invention relates to extracellular vesicles (EVs) as a novel therapeutic approach to lysosomal storage disorders (LSD). More specifically, the invention relates to the use of various protein engineering strategies for improving loading of hard-to-load LSD-related proteins and targeting of the resultant EVs to tissues and organs of interest.
    Type: Application
    Filed: November 13, 2018
    Publication date: December 24, 2020
    Inventors: Justin HEAN, Per LUNDIN, Andre GORGENS
  • EXOSOMES COMPRISING THERAPEUTIC POLYPEPTIDES
    Publication number: 20190167810
    Abstract: The present invention pertains to an inventive release mechanism for extracellular vesicle (EV)-mediated intracellular and intramembrane delivery of therapeutic polypeptides. More specifically, the invention relates to EVs comprising polypeptide constructs which comprise a therapeutic polypeptide releasably attached to an exosomal polypeptide. Furthermore, the present invention pertains to manufacturing methods, pharmaceutical compositions, medical uses and applications, and various other embodiments related to the inventive EVs.
    Type: Application
    Filed: May 25, 2017
    Publication date: June 6, 2019
    Applicants: Evox Therapeutics Ltd, Oxford University Innovation
    Inventors: Justin HEAN, Imre MAGER, Matthew WOOD, Samir EL ANDALOUSSI, Oscar WIKLANDER, Joel NORDIN
  • INHIBITION OF VIRAL GENE EXPRESSION
    Publication number: 20140350080
    Abstract: This invention relates to modified short interfering RNA (siRNA) nucleic acid molecules, particularly siRNA's which have been modified by the addition of a 2-0-guanidinopropyl (GP) modified nucleoside. In particular the invention relates to modified siRNAs which are capable of silencing target sequences, methods of treating and preventing infection by using the siRNAs, medicaments containing the siRNAs and use of the siRNAs.
    Type: Application
    Filed: October 26, 2012
    Publication date: November 27, 2014
    Applicant: UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG
    Inventors: Patrick Arbuthnot, Justin Hean, Abdullah Ely, Musa Marimani, Jolanta Brzezinska, Jennifer D'Onofrio, Maximilian C.R. Buff, Joachim W. Engels, Stefan Bernhardt